Helmholtz Munich Receives Award from Breakthrough T1D to Fund AI-driven Diabetes Research
Researchers at Helmholtz Munich have received an award from Breakthrough T1D, a leading global type 1 diabetes (T1D) research and advocacy organization, to fund a new diabetes research project. The project will leverage advanced artificial intelligence (AI) and single-cell genomics to create a comprehensive map of the differentiation process of stem cells into pancreatic beta cells. Led by Fabian Theis, a renowned expert in AI and single-cell genomics, and Heiko Lickert, a leading specialist in beta cell and stem cell biology, this research aims to pave the way for innovative and personalized beta cell replacement therapies.
Leveraging AI and Single-Cell Genomics for Diabetes Research
The primary goal of this project is to create a comprehensive and detailed map of the differentiation process by which stem cells develop into insulin-producing beta cells and identify the key drivers of this transformation. By integrating single-cell genomics with advanced artificial intelligence (AI) techniques, the project aims to enhance our understanding of beta cell differentiation and functional maturation from stem cells. “We are excited to embark on this journey. We expect to be able to create stem cell-derived beta cells and islets that mimic the human body counterpart, ultimately contributing to the development of innovative stem cell-based therapies for type 1 diabetes patients,” says Prof. Heiko Lickert.
AI offers unprecedented opportunities in the field of beta cell replacement therapies. “While significant progress has been made in creating beta cells from stem cells, the application of advanced AI techniques in this area remains largely untapped,” states Prof. Fabian Theis. “Integrating AI into our research will allow us to refine stem cell therapies, making them more effective and personalized.”
Anticipated Benefits for T1D Patients
By improving the efficiency and effectiveness of beta cell replacement therapies, the project aims to offer personalized treatment options that address individual patients' needs. This could lead to more precise insulin production and better management of blood sugar levels, reducing the long-term complications associated with T1D.
“At Breakthrough T1D we are committed to funding research that has the potential to transform the lives of those living with type 1 diabetes as we drive toward cures,“ says Nicholas Mamrak, PhD, research scientist at Breakthrough T1D. “This project represents a significant step forward in building our understanding of beta cell development. By harnessing the power of AI and single-cell genomics, the research has the potential to unlock new possibilities in beta cell therapy and improve the lives of millions of people living with T1D worldwide.”
